CARL CARLSMED, INC.

Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0001794546
AI RATING
HOLD
65% Confidence

Investment Thesis

CARL demonstrates strong top-line momentum with 85.9% revenue growth and industry-leading 77.1% gross margins, but faces critical profitability challenges with -57.6% operating margins and -13M negative operating cash flow. The company's strong balance sheet (73M cash, 0.17x D/E) provides 5-6 years of runway, but path to profitability remains unproven and represents the primary execution risk.

Strengths

  • + Exceptional revenue growth of 85.9% YoY demonstrates strong product-market fit in surgical instruments sector
  • + Industry-leading gross margin of 77.1% indicates efficient manufacturing and robust unit economics at the product level
  • + Fortress balance sheet with 73M cash, minimal debt (0.17x D/E), and 11.88x current ratio provides financial flexibility to invest in growth and weather operational challenges

Risks

  • ! Severe operating losses (-9.3M) and negative net income (-8.7M) indicate core business operations are unprofitable and not scalable at current structure
  • ! Negative operating cash flow (-13M) and -81.2% FCF margin reveals cash burn despite positive revenues; company loses 81 cents in cash for every dollar earned
  • ! Unsustainably high operating expenses relative to revenue scale: 77.1% gross margin collapses to -57.6% operating margin, suggesting R&D/SG&A expenses exceed revenue by 134.7% of sales
  • ! Cash sustainability: 73M reserves consumed at 13M annually provides only ~5.6 year runway before depletion if losses persist

Key Metrics to Watch

Financial Metrics

Revenue
16.1M
Net Income
-8.7M
EPS (Diluted)
$-0.32
Free Cash Flow
-13.1M
Total Assets
118.8M
Cash
73.0M

Profitability Ratios

Gross Margin 77.1%
Operating Margin -57.6%
Net Margin -54.0%
ROE -9.4%
ROA -7.3%
FCF Margin -81.2%

Balance Sheet & Liquidity

Current Ratio
11.88x
Quick Ratio
11.67x
Debt/Equity
0.17x
Debt/Assets
22.3%
Interest Coverage
-29.83x
Long-term Debt
15.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-07T08:19:25.455104 | Data as of: 2026-03-31 | Powered by Claude AI